MAX BioPharma is a privately-held preclinical stage biopharmaceutical company based in Los Angeles, California. They are focused on developing novel small molecule lipids as drug candidates to address debilitating and fatal human diseases, pioneering the field of Oxysterol Therapeutics with a strong intellectual property portfolio.
Their mission is to revolutionize the approach to serious human diseases by leveraging their expertise in oxysterol-based interventions. MAX BioPharma's primary focus areas include spine fusion, with their investigational device Oxy133 targeting specialized stem cells for bone formation, and non-alcoholic steatohepatitis (NASH), where they are developing Oxy210 as a safe and effective treatment with antifibrotic and anti-inflammatory properties.
Generated from the website
